Kevin Zeeck, MD
Urology · Menomonee Falls, WINPI 1598108458
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,788 of the $2,672 with a category attached, or 66.9%. Sanofi accounts for 66.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $1,896 and has fallen 88.8% since, to $212 in 2024.
Across 13 payments — averaging $205.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- Boston Scientific$818
- Medtronic$53
- AbbVie$14
What the payments were for
- Consulting fees$1,78867%
- Food & beverage$87033%
- Education$141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $1,788 |
| Boston Scientific | 9 | $818 |
| Medtronic | 2 | $53 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEVTANA$1,788
- LithoVue$243
- SpaceOAR System$150
- GREENLIGHT$149
- SPACEOAR$108
How this compares
$2,672 in reported general payments places this provider in the 70th percentile of 215 urology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 114 | $104,037 |
| GemtesaVibegron | 11 | $12,935 |
| Tamsulosin Hcl | 704 | $10,729 |
| Estradiol | 93 | $6,476 |
| Silodosin | 38 | $5,028 |
| Solifenacin Succinate | 47 | $1,721 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,450 |
| NitrofurantoinNitrofurantoin Macrocrystal | 14 | $868 |
| Tadalafil | 21 | $814 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 33 | $751 |
| Finasteride | 64 | $720 |
| Cephalexin | 82 | $530 |
| Testosterone Cypionate | 11 | $526 |
| Nystatin | 20 | $296 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 55 | $229 |
Paid to pharmacies, not to this prescriber.
Other urology in Menomonee Falls
- Dan GralnekMadison$142K
- Amy GuiseMilwaukee$106K
- Christopher ManakasMadison$87K
- Bahareh Alavi-DunnGreen Bay$62K
- Javier SantiagoMadison$57K
- Kevin FlynnNeenah$56K
- Margaret KnoedlerMadison$31K
- Jeremy ReesePleasant Prairie$27K
- Edwin AbelMadison$22K
- Christopher WalshWauwatosa$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.